Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multi-center study

Donald P. Tashkin, Kumar Ashutosh, Eugene R. Bleecker, E. James Britt, David W. Cugell, Joseph M. Cummiskey, Lawrence Delorenzo, Murray J. Gilman, Gary N. Gross, Nicholas J. Gross, Arthur Kotch, Sambasiva Lakshminarayan, George Maguire, Matthew Miller, Alan Plummer, Attilio Renzetti, Marvin A. Sackner, Morton S. Skoroqin, Adam Wanner, Suetaro Watanabe

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalThe American Journal of Medicine
Volume81
Issue number5 SUPPL. 1
DOIs
StatePublished - Nov 14 1986
Externally publishedYes

Fingerprint

Metaproterenol
Ipratropium
Bronchodilator Agents
Cholinergic Antagonists
Chronic Obstructive Pulmonary Disease
Safety
Vital Capacity
Forced Expiratory Volume
Tremor
Aerosols
Ammonium Compounds
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease : A 90-day multi-center study. / Tashkin, Donald P.; Ashutosh, Kumar; Bleecker, Eugene R.; Britt, E. James; Cugell, David W.; Cummiskey, Joseph M.; Delorenzo, Lawrence; Gilman, Murray J.; Gross, Gary N.; Gross, Nicholas J.; Kotch, Arthur; Lakshminarayan, Sambasiva; Maguire, George; Miller, Matthew; Plummer, Alan; Renzetti, Attilio; Sackner, Marvin A.; Skoroqin, Morton S.; Wanner, Adam; Watanabe, Suetaro.

In: The American Journal of Medicine, Vol. 81, No. 5 SUPPL. 1, 14.11.1986, p. 81-90.

Research output: Contribution to journalArticle

Tashkin, DP, Ashutosh, K, Bleecker, ER, Britt, EJ, Cugell, DW, Cummiskey, JM, Delorenzo, L, Gilman, MJ, Gross, GN, Gross, NJ, Kotch, A, Lakshminarayan, S, Maguire, G, Miller, M, Plummer, A, Renzetti, A, Sackner, MA, Skoroqin, MS, Wanner, A & Watanabe, S 1986, 'Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multi-center study', The American Journal of Medicine, vol. 81, no. 5 SUPPL. 1, pp. 81-90. https://doi.org/10.1016/0002-9343(86)90468-7
Tashkin, Donald P. ; Ashutosh, Kumar ; Bleecker, Eugene R. ; Britt, E. James ; Cugell, David W. ; Cummiskey, Joseph M. ; Delorenzo, Lawrence ; Gilman, Murray J. ; Gross, Gary N. ; Gross, Nicholas J. ; Kotch, Arthur ; Lakshminarayan, Sambasiva ; Maguire, George ; Miller, Matthew ; Plummer, Alan ; Renzetti, Attilio ; Sackner, Marvin A. ; Skoroqin, Morton S. ; Wanner, Adam ; Watanabe, Suetaro. / Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease : A 90-day multi-center study. In: The American Journal of Medicine. 1986 ; Vol. 81, No. 5 SUPPL. 1. pp. 81-90.
@article{23d9f7b187454a9bacb10df6d1c5d7a9,
title = "Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multi-center study",
abstract = "The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.",
author = "Tashkin, {Donald P.} and Kumar Ashutosh and Bleecker, {Eugene R.} and Britt, {E. James} and Cugell, {David W.} and Cummiskey, {Joseph M.} and Lawrence Delorenzo and Gilman, {Murray J.} and Gross, {Gary N.} and Gross, {Nicholas J.} and Arthur Kotch and Sambasiva Lakshminarayan and George Maguire and Matthew Miller and Alan Plummer and Attilio Renzetti and Sackner, {Marvin A.} and Skoroqin, {Morton S.} and Adam Wanner and Suetaro Watanabe",
year = "1986",
month = "11",
day = "14",
doi = "10.1016/0002-9343(86)90468-7",
language = "English",
volume = "81",
pages = "81--90",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5 SUPPL. 1",

}

TY - JOUR

T1 - Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease

T2 - A 90-day multi-center study

AU - Tashkin, Donald P.

AU - Ashutosh, Kumar

AU - Bleecker, Eugene R.

AU - Britt, E. James

AU - Cugell, David W.

AU - Cummiskey, Joseph M.

AU - Delorenzo, Lawrence

AU - Gilman, Murray J.

AU - Gross, Gary N.

AU - Gross, Nicholas J.

AU - Kotch, Arthur

AU - Lakshminarayan, Sambasiva

AU - Maguire, George

AU - Miller, Matthew

AU - Plummer, Alan

AU - Renzetti, Attilio

AU - Sackner, Marvin A.

AU - Skoroqin, Morton S.

AU - Wanner, Adam

AU - Watanabe, Suetaro

PY - 1986/11/14

Y1 - 1986/11/14

N2 - The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.

AB - The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.

UR - http://www.scopus.com/inward/record.url?scp=0023048731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023048731&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(86)90468-7

DO - 10.1016/0002-9343(86)90468-7

M3 - Article

C2 - 2947465

AN - SCOPUS:0023048731

VL - 81

SP - 81

EP - 90

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5 SUPPL. 1

ER -